Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer

被引：3
|
作者：
Chen, S. [1 ]
Lin, Y. [2 ]
Cui, Y. [1 ]
Zhou, C. [3 ]
An, H. [3 ]
Huang, J. [1 ]
Su, Z. [1 ]
McGowan, E. [4 ]
机构：
[1] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Guangdong Prov Engn Res Ctr Esophageal Canc Preci, Guangzhou, Peoples R China
[2] Univ Technol Sydney, Sch Life Sci, Sydney, NSW, Australia
[3] Guangzhou Anjie Biomed Technol Co Ltd, Guangzhou, Peoples R China
[4] Univ Technol Sydney, Ultimo, Australia
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-258
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [1] Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer
    Lin, Y.
    Chen, S.
    Zhong, S.
    An, H.
    Yin, H.
    McGowan, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 15 - 15
  • [2] Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study
    Chen, S.
    Lin, Y.
    Zhong, S.
    An, H.
    Lu, Y.
    Yin, M.
    Liang, W.
    McGowan, E. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
    McGowan, Eileen
    Lin, Qimou
    Ma, Guocai
    Yin, Haibin
    Chen, Size
    Lin, Yiguang
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [4] Anti-MUC1*CAR T for solid tumors
    Bamdad, Cynthia C.
    Stewart, Andrew K.
    Smagghe, Benoit J.
    Huang, Pengyu
    Deary, Luke T.
    Glennie, Nelson D.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
    Najafi, Sajad
    Mortezaee, Keywan
    LIFE SCIENCES, 2024, 338
  • [6] Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer
    Lin, Yiguang
    Yin, Haibin
    Zhou, Chao
    Zhou, Ling
    Zeng, Yanyi
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] A novel anti-MUC1 CAR T cell drives immunity to pancreatic cancer
    Yazdanifar, Mahboubeh
    Zhou, Ru
    Wu, Shu-ta
    Grover, Priyanka
    Mukherjee, Pinku
    CANCER RESEARCH, 2017, 77
  • [8] CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
    Andreu-Saumell, Irene
    Rodriguez-Garcia, Alba
    Muehlgrabner, Vanessa
    Gimenez-Alejandre, Marta
    Marzal, Berta
    Castellsague, Joan
    Braso-Maristany, Fara
    Calderon, Hugo
    Angelats, Laura
    Colell, Salut
    Nuding, Mara
    Soria-Castellano, Marta
    Barbao, Paula
    Prat, Aleix
    Urbano-Ispizua, Alvaro
    Huppa, Johannes B.
    Guedan, Sonia
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [9] The safety of CAR-T cells and PD-1 antibody combination on an experimental model
    Nguyen, Hien Hanh
    Bui, Khac Cuong
    Nguyen, Thi Mai Ly
    Pham, Chi
    Nham, Thi Phuong Linh
    Ngo, Thu Hang
    Ho, Viet Hoanh
    Ta, Viet Hung
    Bozko, Przemyslaw
    Nguyen, Linh Toan
    Can, Van Mao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 649 : 25 - 31
  • [10] Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer
    Chen, Size
    Lin, Yiguang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345